immunotoxin


Also found in: Dictionary, Thesaurus, Medical, Financial, Wikipedia.

immunotoxin

[‚im·yə·nō′täk·sən]
(immunology)
Conjugate of antibody and toxic protein such that the specificity of the antibody molecule is combined with the cytotoxic property of the toxin.
References in periodicals archive ?
Speculating that immunotoxins and interleukin-2 generate leaky blood vessels in the same way, Vitetta's team compared the proteins.
The report includes a compilation of current active projects in research and development of immunotoxins in oncology.
This is the first recombinant immunotoxin comprising a humanized antibody against CD74 and an engineered ribonuclease (RNase).
Today Enzon also announced that it has decided to discontinue its collaborative research and development program with the National Institutes of Health (NIH) for the recombinant immunotoxin SS1P.
The fourth poster described the construction, characterization, and in vitro cytotoxiciy of a novel immunotoxin fusion protein consisting of two ranpirnase (rpRNase) molecules fused to an anti-CD74 humanized antibody.
Also presented were results from a Phase 2 study for Pegamotecan, a novel pegylated camptothecin conjugate, for the treatment of gastric and gastroesophageal cancers and results from a National Cancer Institute (NCI) Phase 1 study for SS1P, a recombinant immunotoxin under investigation as a potential therapy for mesothelin-expressing cancers, (e.
Native ricin A chain coupled to tumor-specific monoclonal antibodies has been used as an immunotoxin to treat patients with B-cell leukemia and lymphoma.
for immunotoxins - including agents in clinical development -- Biosimilar insulins likely from 2015 - transformation of that market -- Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.
Keynote Presentation: "Novel Approach to B and T Epitope Removal from Immunotoxins with Retention of High Cytotoxic Activity," featuring Ira Pastan, M.
Oncomatrix carries out the development of Diagnostic devices and Antibody-Drug Conjugates and Immunotoxins against these novel targets, in collaboration with reference research centers, universities and hospitals in Europe and USA, such as National Jewish Health, Case Western Reserve University, University of Stuttgart, Hospital Universitario Marques de Valdecilla and Hospital Central de Asturias.
They then introduced special antibodies with toxins and found that the immunotoxins penetrated the leukaemia cells and killed them faster.
This makes it much easier for antibody-based drugs, known as immunotoxins, to attack the cancerous cells.